Crinetics Pharmaceuticals, Inc. 4

President & CEO Richard Scott Struthers had all of his and related entities’ Crinetics common shares and in-the-money stock options canceled and cashed out at the $85.00 per share merger price, leaving him with no remaining equity in the company.

On September 1, 2026, in connection with the cash acquisition of Crinetics Pharmaceuticals, Inc. by Vertex Pharmaceuticals at $85.00 per share, President & CEO Richard Scott Struthers reported the automatic cancellation of all of his and his related entities’ holdings of Crinetics common stock and equity awards. This included the conversion of 248,043 directly held common shares and 1,000 shares held indirectly by his spouse, as well as 136,805 shares held by Family Trust 1, 106,000 by Family Trust 2, 110,000 by Family Trust 3, 100,000 by Family Trust 4, 111,100 each by Family Trusts 5 through 8, and 80,000 by a Charitable Trust, into the right to receive $85.00 per share in cash, after which all of these positions showed zero share ownership. In addition, 176,663 common shares reported in the derivative section were similarly cashed out at $85.00 per share, and a series of vested stock options with exercise prices below $85.00 (covering 172,281; 195,578; 259,058; 244,205; 287,700; 240,000; 313,000; and 228,000 underlying shares, respectively) were canceled and converted into cash equal to $85.00 minus the stated exercise price per share. Post‑merger, Struthers reported no remaining ownership of Crinetics common stock or options, as all equity was effectively liquidated for cash consideration under the merger agreement.

Filing Facts

CIK

1658247

Ticker

CRNX

Form

4

Source Type

fda

Accession

0001628280-26-059882

Alert Tier

7